Advancing therapy in T2DM with injectables, i.e., basal insulin (BI) and GLP‐1 receptor agonists (GLP‐1RAs) is recommended after the failure of oral glucose lowering agents (OGLAs), BI alone, or BI in combination with OGLAs, especially in persons with, or at high risk of atherosclerotic cardiovascular disease (ASCVD). The gene discussed is INS; the disease is atherosclerosis.